Thu, Dec 25, 2014, 3:09 PM EST - U.S. Markets closed for Christmas

Recent

% | $
Quotes you view appear here for quick access.

Immune Pharmaceuticals, Inc. Message Board

mdpetrosky 249 posts  |  Last Activity: Dec 22, 2014 7:18 PM Member since: Feb 7, 2011
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • mdpetrosky by mdpetrosky Dec 5, 2014 1:01 AM Flag

    one_up_on_wall_street • Oct 27, 2014 10:03 AM Flag

    1
    users liked this posts

    users disliked this posts
    0
    Reply

    Some very interesting notes in the Annual Report that came out last night:
    .

    - "Having now achieved certification in all 50 U.S. States for high complexity molecular testing, new products can be added to the Company’s portfolio of tests and taken to market in the U.S. using our existing sales force, with no further material regulatory steps being necessary. The Company continues to look for synergistic assets that can be deployed through our existing sales and marketing infrastructure."

    - "Discussions regarding the Company’s RareCellectTM project continue with a number of potential partners with a view to completing a potential transaction during the latter part of CY 2014."

    - "By benchmarking ourselves against other successful companies in our sector such as Myriad Genetics and Genomic Health we can determine that the number of tests performed by the Company in year three from launch are broadly on track in the adoption phase of market acceptance as compared to other, now highly successful products offered by these large U.S. companies. The addition of the new generation test, BREVAGenplus will only improve the market acceptance and adoption."

    - On Brevagenplus... "In 2014 the Company worked with U.S. consultants to develop clinical utility study designs that would be acceptable to Insurers, Payers and physicians, to further demonstrate the clinical value of BREVAGen. Study designs were developed incorporating feedback from medical directors and physicians and collaborators within the clinical community are being identified. Studies are anticipated to commence in late 2014 and provide initial data in mid to late 2015 to allow contracting discussions with Insurers to commence." Less

    Sentiment: Strong Buy

  • mdpetrosky by mdpetrosky Nov 18, 2014 8:38 PM Flag

    Home » Biotech & Pharma » iBio (NYSEMKT:IBIO) Joins Hands With Caliber Biotherapeutics

    iBio (NYSEMKT:IBIO) Joins Hands With Caliber Biotherapeutics

    by Mike Rosenberg

    November 18, 2014

    Biotech & Pharma

    No Comments

    50 views




    iBio, Inc. (NYSEMKT:IBIO) and Caliber Biotherapeuticshave executed an agreement for an emergency useof theiBioLaunch™ platform for production of antibodies by Caliber that target the Ebola virus.

    Collaborative Relationship of iBio and Caliber:

    As announced previously on 15thJanuary and 16th October, 2014, iBio Inc. and Caliber Biotherapeuticshave had a collaborative relationship that is reflected by a License and Collaboration Agreement that was signed on 14th February, 2013. Both iBioInc. and Caliber Biotherapeuticshave been involved in examining how the companies could use their technologies and the facilities in assisting the governments to address the issue of Ebola epidemic since early September.



    Other Collaborations of Two Companies:

    iBio, Inc. (NYSEMKT:IBIO). and Caliber Biotherapeutics are also are collaborating on certain commercial opportunities for the recombinant antibodies and antibody-related proteins that could benefit from the efficiency, speed, and cost advantages of production of pharmaceutical proteins in plants rather than bioreactor-based manufacturing methods that use Chinese hamster ovary (CHO) cells.





    License Expands Freedom of Caliber Biotherapeutics:

    The license that has been announced expands the freedom of Caliber Biotherapeuticsto operate under the issued U.S. patents and related intellectual property of iBio Inc.that would enable Caliber in assisting the U.S. government by the manufacture of some experimental drugs that would address the Ebola virus outbreak. Caliber Biotherapeuticsoperates the world’s largest capacity cGMP manufacturing facility that is capable to use the technology of iBio, Inc. for the production of monoclonal antibodies, vaccines and other biotherapeutics.

    More AboutiBio, Inc.:

    iBio, Inc. (NYSEMKT:IBIO) owns the iBioLaunch™ platform, which is a transformative technology for developing and producing biologics by using transient gene expression in green plants that have not been modified. The company is involved in the development of a proprietary product that would be used for the treatment of systemic sclerosis, idiopathic pulmonary fibrosis and other fibrotic diseases by using its iBioLaunch platform. iBio, Inc. also offers the technology licenses to others and it provides collaborators the full support for turn-key implementation of company’s technology for protein therapeutics and vaccines.

  • mdpetrosky mdpetrosky Nov 11, 2014 6:30 PM Flag

    Up tonight and blastoff tomorrow.

  • mdpetrosky by mdpetrosky Nov 26, 2014 9:43 AM Flag

    Great day

  • No good news until then, please.

  • Reply to

    Short term catalysts

    by one_up_on_wall_street Dec 5, 2014 3:19 PM
    mdpetrosky mdpetrosky Dec 5, 2014 3:37 PM Flag

    GE has change there name 3 times in the early days.

    Sentiment: Strong Buy

  • mdpetrosky by mdpetrosky Dec 4, 2014 9:53 PM Flag

    Following the acquisition of BREVAGen™, a proprietary breast cancer risk assessment test, Genetic Technologies has established operations in the US enabling us to offer this exciting test in all 50 states. Less

    Sentiment: Strong Buy

    Sentiment: Strong Buy

  • mdpetrosky mdpetrosky Dec 4, 2014 8:07 PM Flag

    BREVAGen logo

    Listed on the ASX (GTG) and NASDAQ (GENE), Genetic Technologies has created a successful multi-faceted genetic testing business together with expertise in the intellectual property field. The Company partners with world leading suppliers, clinical researchers and academic collaborators.


    Genetic Technologies

    Following the acquisition of BREVAGen™, a proprietary breast cancer risk assessment test, Genetic Technologies has established operations in the US enabling us to offer this exciting test in all 50 states.

    Sentiment: Strong Buy

  • mdpetrosky mdpetrosky Dec 8, 2014 7:13 PM Flag

    More then 3/4 board were trying to trash the stock as a pump and dump. Same with Market Pulse calling it a pump and dump. They wanted to buy lower.

    Sentiment: Strong Buy

  • Reply to

    News out - IBIO out of the race

    by mark.pretzel Nov 11, 2014 4:02 PM
    mdpetrosky mdpetrosky Nov 11, 2014 5:37 PM Flag

    Link

    Sentiment: Strong Buy

  • mdpetrosky mdpetrosky Nov 8, 2014 6:50 PM Flag

    Buy more because gas prices and oil will go up for the Holidays.

    Sentiment: Buy

  • Reply to

    NEWS

    by mdpetrosky Dec 4, 2014 9:53 PM
    mdpetrosky mdpetrosky Dec 4, 2014 10:21 PM Flag

    On GENE website.

    Sentiment: Strong Buy

  • All the way down. We will base for a few days then back up.

    Sentiment: Strong Buy

  • mdpetrosky by mdpetrosky Nov 26, 2014 10:44 AM Flag

    Don't do them

    Sentiment: Strong Buy

  • We will see chaser next couple of weeks.

    Sentiment: Strong Buy

  • Reply to

    OLD NEWS !!!

    by ambo_988 Oct 6, 2014 4:57 PM
    mdpetrosky mdpetrosky Oct 6, 2014 5:25 PM Flag

    Old news, are you short?

    Sentiment: Strong Buy

  • mdpetrosky by mdpetrosky Oct 3, 2014 4:03 PM Flag

    think the same thing, I wonder if Ebola links are being investigated with Vicals CMV vaccine research programs (ASP0113 Therapeutic CMV Vaccine). check out this link as it states "A CMV-based vaccine confers protection against ebola virus in mice." among the action points.

  • It will run

    Sentiment: Strong Buy

  • mdpetrosky by mdpetrosky Oct 20, 2014 11:14 AM Flag

    Large buys

    Sentiment: Strong Buy

IMNP
1.89+0.02(+1.07%)Dec 24 12:58 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Yahoo! Inc.
NASDAQWed, Dec 24, 2014 1:00 PM EST
Virgin America Inc.
NASDAQWed, Dec 24, 2014 1:00 PM EST